Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with *Demodex* Mites Topline Data Presentation

December 2023



## **Legal Disclaimer**

This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations about future events that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including any statements regarding the timing, objectives, and results of the clinical trials including the complete clinical results of the Ersa trial and anticipated regulatory and development milestones are forward-looking statements. The words "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements (expressed or implied) are made about the accuracy of any such forward-looking statements. Important factors that could cause our actual results to differ materially are detailed from time to time in the reports we file with the Securities and Exchange Commission, copies of which are posted on our website and are available from us without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties.





# Ersa Phase 2a Study Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with *Demodex* Mites


- TP-03 (lotilaner ophthalmic solution 0.25%) demonstrated statistically significant improvements compared to baseline in objective measures of meibomian gland function at 6 and 12 weeks
  - Meibomian gland secretion score (MGSS) at Day 43 (6 weeks) and Day 85 (12 weeks) demonstrated a statistically significant and clinically meaningful improvement over baseline
  - Number of glands secreting clear meibum demonstrated statistically significant and clinically meaningful improvement from baseline to Day 43 and 85
  - There were no significant differences between BID and TID across all measures
- Collarette cure and lid margin erythema cure demonstrated statistically significant improvement consistent with prior TP-03 studies
- TP-03 was generally well-tolerated
- FDA discussion planned for 2024





#### **Ersa Phase 2a Study Overview**


- Randomized, Double-Masked, Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens (BID vs TID) of TP-03 for the Treatment of MGD in Patients with *Demodex* mites
- 39 patients randomized to BID/TID arms
- Endpoints collected included safety assessments, meibomian gland function, DB endpoints and patient-reported symptoms





## **TP-03 Treatment Significantly Improves Meibomian Gland Function**

- Demonstrated a significant and clinically meaningful increase from baseline that was observed in the mean MGSS of 10.5 (± 1.6 standard error, SE) and 11.7 (± 1.9 SE) for the BID and TID arms, respectively, at Day 85 (p < 0.001)</li>
- No statistically significant differences between BID and TID treatment groups






\*MGSS Score Range 0-45

#### **TP-03 Treatment Significantly Improves Meibomian Gland Secretion**

- Demonstrated improvement in the mean number of meibomian glands secreting clear liquid from baseline that was also • statistically significant and clinically meaningful, with an increase of 4.8 (± 0.8 SE) and 5.3 (± 1.1 SE) glands for the BID and TID arms, respectively, at Day 85 (p < 0.001)
- No statistically significant differences between BID and TID treatment groups ٠





## **Ersa MGD Phase 2a Study Safety and Tolerability**

#### • TP-03 was generally well tolerated following 12 week of treatment period

- Most Adverse Events (AEs) were mild
  - 2 Drug-related AEs were mild (5.1%): 1 case of ocular discomfort in the BID arm and 1 case of conjunctivitis in the TID arm

#### No related Serious Adverse Events (SAEs)

- 1 unrelated SAE of presyncope
- No treatment-related discontinuations



